Evidence map›Paper›PMID 39242418›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Lipocalin-2 expression in papillary thyroid carcinoma and its association with clinicopathological characteristics.

Mustafa Alkaya, Ali Bayram, Mehmet Yaşar, Merve Doğan, Hümeyra Gençer

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mustafa AlkayaDepartment of ENT, Kayseri City Training and Research Hospital, Kayseri, Turkey. alkaya.mustafa90@gmail.com.ORCID http://orcid.org/0000-0003-0202-6979
Ali BayramDepartment of ENT, Kayseri City Training and Research Hospital, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-0061-1755
Mehmet YaşarDepartment of ENT, Kayseri City Training and Research Hospital, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-8246-6853
Merve DoğanDepartment of Pathology, Kayseri City Training and Research Hospital, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-8742-5014
Hümeyra GençerDepartment of Nuclear Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-5081-2117

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe present study aimed to assess Lipocalin-2 (LCN2) expression in patients with papillary thyroid cancer (PTC) and to compare it with multinodular goitre (MNG). We also investigated the correlation between LCN2 expression and clinicopathologic characteristics.

methodsThis retrospective study included 63 surgically treated adult patients with papillary carcinoma and 65 adult patients with a MNG. Age, gender, physical, radiological and histopathological examinations, and surgical data of the patients were extracted from the hospital records. Size, histological subtype, capsule invasion, multifocality, extrathyroidal extension (ETE), lymph node metastasis (LNM), and immunohistochemical (IHC) studies of the tumour were recorded from the final histopathological reports of patients with PTC. The patient groups were compared in terms of LCN2 expression. The relationships between LCN2 expression and clinicopathological and other IHC parameters were also evaluated in patients with PTC.

resultsLCN2 expression was significantly higher in the PTC group than in the control group. No significant correlation was demonstrated between LCN2 expression and the presence of multifocal disease, capsular invasion, vascular invasion, ETE, and LNM. There was a moderate positive correlation between LCN2 and human bone marrow endothelial cell marker-1 (HBME-1) expressions, however, no correlation was found between LCN2 and cytokeratin-19 (CK19), CD56, and galectin-3.

conclusionLCN2 expression may be a useful biomarker in differentiating benign and malignant lesions of the thyroid gland; however, its expression pattern may not be associated with clinicopathologic characteristics of the PTC and should be investigated in further studies with larger clinical samples.

Indexed as

Goiter, NodularLipocalin-2Thyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedBiomarkers, TumorCarcinoma, PapillaryFemaleHumansImmunohistochemistryMaleMiddle AgedRetrospective StudiesBiomarkers, TumorLCN2 protein, humanLipocalin-2Differential diagnosisImmunohistochemistryLipocalin-2Thyroid neoplasms

Identifiers

PMID39242418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.